The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.

Despite competitive pressures in the obesity market, long-term investors may stay invested in NVO stock due to strong demand ...

FRANKFURT, Germany (AP) — Pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said Friday ...

A new film from Eli Lilly sounds like a recruitment ad, but it doubles as a brand manifesto to showcase the pharmaceutical ...

Unlike the Get Better campaign — which was built throughout last year — Seeking launched with a full body of creative work, according to its chief corporate brand officer Lina Polimeni.

Explore why INmune Bio, Inc. is a speculative Strong Buy for high-risk investors. Click for the upcoming catalysts that make ...

During a live event, Xiuning Le, MD, PhD, discussed clinical trials of supportive care for infusion reaction and skin rash ...

The trial aims to enroll 40 patients with FGFR alterations across the US, who won't need to travel far to receive care.

The drugmaker's approved treatment, Kisunla (donanemab), works by binding to deposited amyloid plaque in the brain. Its phase 3 Alzheimer's asset, remternetug, also binds to amyloid plaques. It is ...